Traditionally, migraine is thought of as an issue of lost productivity, but there is evidence that there are direct costs on the medical claims side, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Traditionally, migraine is thought of as an issue of lost productivity, but there is evidence that there are direct costs on the medical claims side, said Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Group on Health.
Transcript
How are employers managing their employees who have migraines that might result in presenteeism or absenteeism?
So, historically, employers have not paid very much attention to migraine. They don’t see it a lot in their direct costs. It’s actually there in direct costs. We just completed a study that shows that migraineurs do cost significantly more on the medical claims side than non-migraineurs. But it’s traditionally thought of as a lost-productivity issue—absence from the job or not being able to do the full days’ job, which is call presenteeism.
With a new class of migraine preventive drugs that are not inexpensive, I think there is some renewed employer interest in at least knowing how many migraineurs do we have, what might the cost be to us in the future? So, we are doing a lot of education of employers on how to identify the migraineurs, because migraine is actually highly underdiagnosed. And so, if you look at your claims data, you might say, “I have 2% or 3% migraine rate,” when we know that the truth is for younger females the migraine rate could be 15% to 20%.
So, employers need to look at their data differently. And also need to get, I think, a little bit more invested in: how are we actually going to measure the indirect costs of the lost productivity? Most employers I talk to say, “We know lost productivity is important. W either don’t believe the measures are valid or we don’t know how to implement the measures. Or my [chief financial officer] is not asking for that information.”
So, there’s a tremendous amount that has to change—not just for migraine but for other conditions—to say, “Lost productivity is a truly important cost that needs to be managed.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More